Boelen, L;
Debebe, B;
Silveira, M;
Salam, A;
Makinde, J;
Roberts, C;
Wang, E;
Frater, J;
Gilmour, J;
Twigger, K;
et al.
Boelen, L; Debebe, B; Silveira, M; Salam, A; Makinde, J; Roberts, C; Wang, E; Frater, J; Gilmour, J; Twigger, K; Ladell, K; Miners, K; Jayaraman, J; Traherne, J; Price, D; Qi, Y; Martin, M; Macallan, DC; IAVI Protocol C Investigators; Thio, C; Astemborski, J; Kirk, G; Donfield, S; Buchbinder, S; Khakoo, S; Goedert, J; Trowsdale, J; Carrington, M; Kollnberger, S; Asquith, B
(2018)
Inhibitory killer-cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV and HTLV-1.
Science Immunology, 3 (29).
eaao2892.
ISSN 2470-9468
https://doi.org/10.1126/sciimmunol.aao2892
SGUL Authors: Macallan, Derek Clive
Abstract
Killer cell immunoglobulin-like receptors (KIRs) are expressed predominantly on natural killer cells, where they play a key role in the regulation of innate immune responses. Recent studies show that inhibitory KIRs can also affect adaptive T cell–mediated immunity. In mice and in human T cells in vitro, inhibitory KIR ligation enhanced CD8+ T cell survival. To investigate the clinical relevance of these observations, we conducted an extensive immunogenetic analysis of multiple independent cohorts of HIV-1–, hepatitis C virus (HCV)–, and human T cell leukemia virus type 1 (HTLV-1)–infected individuals in conjunction with in vitro assays of T cell survival, analysis of ex vivo KIR expression, and mathematical modeling of host-virus dynamics. Our data suggest that functional engagement of inhibitory KIRs enhances the CD8+ T cell response against HIV-1, HCV, and HTLV-1 and is a significant determinant of clinical outcome in all three viral infections.
Statistics
Item downloaded times since 27 Nov 2018.
Actions (login required)
|
Edit Item |